<DOC>
	<DOCNO>NCT00059982</DOCNO>
	<brief_summary>RATIONALE : Perifosine may stop growth tumor cell block enzymes necessary tumor cell growth . PURPOSE : Phase II trial study effectiveness perifosine treat patient locally advance , unresectable , metastatic pancreatic cancer .</brief_summary>
	<brief_title>Perifosine Treating Patients With Locally Advanced , Unresectable , Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine activity perifosine , term objective response , patient locally advance , unresectable , metastatic pancreatic cancer . - Determine response duration , progression-free survival , overall survival patient treated drug . - Determine toxicity drug patient . OUTLINE : This multicenter study . Patients receive oral perifosine every 6 hour total 6 dos daily absence disease progression unacceptable toxicity . Patients follow every 3 month 3 year . PROJECTED ACCRUAL : A total 35-84 patient accrue study within 21 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma pancreas Locally advance , unresectable , metastatic disease Measurable disease No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic WBC least 3,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic AST great 2 time upper limit normal ( ULN ) Bilirubin great 2 time ULN Renal Creatinine great 1.4 mg/dL Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No ongoing active infection No psychiatric illness social situation would preclude study compliance No concurrent illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy pancreatic cancer More 6 month since prior chemotherapy disease Endocrine therapy Not specify Radiotherapy At least 4 week since prior radiotherapy recover Surgery At least 4 week since prior surgery recover Other No concurrent investigational agent pancreatic cancer No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>